Literature DB >> 20956815

Association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ.

Tatyana Shamliyan1, Shi-Yi Wang, Beth A Virnig, Todd M Tuttle, Robert L Kane.   

Abstract

We synthesized the evidence of the association between patient and tumor characteristics with clinical outcomes in women with ductal carcinoma in situ of the breast. We identified five randomized controlled clinical trials and 64 observational studies that were published in English from January 1970 to January 2009. Younger women with clinically presented ductal carcinoma in situ had higher risk of ipsilateral recurrent cancer. African Americans had higher mortality and greater rates of advanced recurrent cancer. Women with larger tumor size, comedo necrosis, worse pathological grading, positive surgical margins, and at a higher risk category, using a composite prognostic index, had worse outcomes. Inconsistent evidence suggested that positive HER2 receptor and negative estrogen receptor status were associated with worse outcomes. Synthesis of evidence was hampered by low statistical power to detect significant differences in predictor categories and inconsistent adjustment practices across the studies. Future research should address composite prediction indices among race groups for all outcomes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20956815      PMCID: PMC5161074          DOI: 10.1093/jncimonographs/lgq034

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  125 in total

1.  Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study.

Authors:  Pamela R Benitez; Oscar Streeter; Frank Vicini; Vivek Mehta; Coral Quiet; Robert Kuske; Mary Katherine Hayes; Doug Arthur; Henry Kuerer; Gary Freedman; Martin Keisch; Thomas Dipetrillo; David Khan; Richard Hudes
Journal:  Am J Surg       Date:  2006-10       Impact factor: 2.565

2.  Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.

Authors:  N Bijker; J L Peterse; L Duchateau; J P Julien; I S Fentiman; C Duval; S Di Palma; J Simony-Lafontaine; I de Mascarel; M J van de Vijver
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

3.  Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients.

Authors:  B Cutuli; C Cohen-Solal-Le Nir; B De Lafontan; H Mignotte; V Fichet; R Fay; V Servent; S Giard; C Charra-Brunaud; H Auvray; F Penault-Llorca; J C Charpentier
Journal:  Eur J Cancer       Date:  2001-12       Impact factor: 9.162

4.  Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast.

Authors:  M J Silverstein; A Barth; D N Poller; E D Gierson; W J Colburn; J R Waisman; P Gamagami
Journal:  Eur J Cancer       Date:  1995       Impact factor: 9.162

5.  Noninvasive ductal carcinoma of the breast: the relevance of histologic categorization.

Authors:  C O Bellamy; C McDonald; D M Salter; U Chetty; T J Anderson
Journal:  Hum Pathol       Date:  1993-01       Impact factor: 3.466

6.  Initial outcomes for patients treated on the American Society of Breast Surgeons MammoSite clinical trial for ductal carcinoma-in-situ of the breast.

Authors:  Jacqueline S Jeruss; Frank A Vicini; Peter D Beitsch; Bruce G Haffty; Coral A Quiet; Victor J Zannis; Angela J Keleher; Delia M Garcia; Howard C Snider; Mark A Gittleman; Eric Whitacre; Pat W Whitworth; Richard E Fine; Stacey Arrambide; Henry M Kuerer
Journal:  Ann Surg Oncol       Date:  2006-05-16       Impact factor: 5.344

7.  Effectiveness of radiation therapy in older women with ductal carcinoma in situ.

Authors:  Benjamin D Smith; Bruce G Haffty; Thomas A Buchholz; Grace L Smith; Deron H Galusha; Justin E Bekelman; Cary P Gross
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

8.  Long-term outcome for mammographically detected ductal carcinoma in situ managed with breast conservation treatment: prognostic significance of reexcision.

Authors:  Neha Vapiwala; Eleanor Harris; Wei-Ting Hwang; Lawrence J Solin
Journal:  Cancer J       Date:  2006 Jan-Feb       Impact factor: 3.360

9.  Noninvasive breast carcinoma: results of a national survey by the American College of Surgeons.

Authors:  D Rosner; R N Bedwani; J Vana; H W Baker; G P Murphy
Journal:  Ann Surg       Date:  1980-08       Impact factor: 12.969

10.  Treatment for ductal carcinoma in situ in an Asian population: outcome and prognostic factors.

Authors:  Esther W L Chuwa; Vincent H S Tan; Puay-Hoon Tan; Wei-Sean Yong; Guy-Hui Ho; Chow-Yin Wong
Journal:  ANZ J Surg       Date:  2008 Jan-Feb       Impact factor: 1.872

View more
  16 in total

1.  Lifestyle factors and the risk of a second breast cancer after ductal carcinoma in situ.

Authors:  Vicki Hart McLaughlin; Amy Trentham-Dietz; John M Hampton; Polly A Newcomb; Brian L Sprague
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-01-08       Impact factor: 4.254

2.  Racial disparities in risk of second breast tumors after ductal carcinoma in situ.

Authors:  Ying Liu; Graham A Colditz; Sarah Gehlert; Melody Goodman
Journal:  Breast Cancer Res Treat       Date:  2014-09-27       Impact factor: 4.872

3.  HER2-Overexpressing Ductal Carcinoma In Situ Associated with Increased Risk of Ipsilateral Invasive Recurrence, Receptor Discordance with Recurrence.

Authors:  Thomas J O'Keefe; Sarah L Blair; Ava Hosseini; Olivier Harismendy; Anne M Wallace
Journal:  Cancer Prev Res (Phila)       Date:  2020-06-03

4.  Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast.

Authors:  Adele A Bailes; Henry M Kuerer; Sara A Lari; Lovell A Jones; Abenaa M Brewster
Journal:  Cancer       Date:  2012-06-26       Impact factor: 6.860

5.  Accelerated partial breast irradiation through brachytherapy for ductal carcinoma in situ: factors influencing utilization and risks of second breast tumors.

Authors:  Ying Liu; Derek T Schloemann; Min Lian; Graham A Colditz
Journal:  Breast Cancer Res Treat       Date:  2015-04-19       Impact factor: 4.872

6.  Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model.

Authors:  Kelli Elizabeth Valdez; Fang Fan; William Smith; D Craig Allred; Daniel Medina; Fariba Behbod
Journal:  J Pathol       Date:  2011-09-26       Impact factor: 7.996

7.  Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile.

Authors:  Satoshi Takahashi; Aye Aye Thike; Valerie Cui Yun Koh; Hironobu Sasano; Puay Hoon Tan
Journal:  Virchows Arch       Date:  2018-07-23       Impact factor: 4.064

8.  Obesity and future prostate cancer risk among men after an initial benign biopsy of the prostate.

Authors:  Andrew Rundle; Michelle Jankowski; Oleksandr N Kryvenko; Deliang Tang; Benjamin A Rybicki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04-23       Impact factor: 4.254

9.  Clinical outcomes of ductal carcinoma in situ of the breast treated with partial mastectomy without adjuvant radiotherapy.

Authors:  Seung Hyun Hwang; Joon Jeong; Sung Gwe Ahn; Hak Min Lee; Hy-De Lee
Journal:  Yonsei Med J       Date:  2012-05       Impact factor: 2.759

10.  Ductal carcinoma in situ: what the pathologist needs to know and why.

Authors:  Anita Bane
Journal:  Int J Breast Cancer       Date:  2013-02-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.